Status:
TERMINATED
An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Anti-TNF Therapy (REPEAT)
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Rheumatoid Arthritis
Eligibility:
All Genders
18+ years
Brief Summary
This observational study will assess the efficacy and safety of MabThera/Rituxan (Rituximab) in patients with active rheumatoid arthritis who have had an inadequate response or are intolerant to anti-...
Eligibility Criteria
Inclusion
- Adult patients, \>/= 18 years of age
- Active Rheumatoid Arthritis
- Inadequate response to anti-TNF
- Eligible for MabThera/Rituxan therapy according to physician's decision
Exclusion
- According to Summary of Product Characteristics
Key Trial Info
Start Date :
February 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 1 2015
Estimated Enrollment :
1240 Patients enrolled
Trial Details
Trial ID
NCT01196780
Start Date
February 1 2010
End Date
October 1 2015
Last Update
November 2 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Bucharest, Romania, 020983